Bioshares 130 There is some validity to the claim that...

Bioshares 130

There is some validity to the claim that Australian investors do not recognise the potential value of biotech assets. Witness G-CSF, which was discovered in Australia but commercialised in the US and has genarated sales of US$7.3 billion for Amgen.
We suggest that a similar investment potential exists with Alchemia’s synthetic heparin, but the wider market is slow to appreciate this.

And we cover the cash positions of 81 companies that report under the 4.7B rule.

Companies covered: ACL